Skip to content
Pharma Observatory a Scientist.com platform

Clinical trial

A Phase 1b Study of Abemaciclib in Combination With Pembrolizumab for Patients With Stage IV Non-Small Cell Lung Cancer or Hormone Receptor Positive, HER2 Negative Breast Cancer

NCT02779751 is registered in ClinicalTrials.gov with Eli Lilly and Company as lead sponsor.

NCT NCT02779751
Email me this page as a PDF

Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.

Get the NCT02779751 report as a PDF

The PDF carries up to 50 rows of each section, where the page shows the first few, with the sources listed. Enter a work email and confirm it from the message we send, and the report follows by email.

Registry record

As filed in ClinicalTrials.gov.

Title
A Phase 1b Study of Abemaciclib in Combination With Pembrolizumab for Patients With Stage IV Non-Small Cell Lung Cancer or Hormone Receptor Positive, HER2 Negative Breast Cancer
Lead sponsor
Eli Lilly and Company
Phase
Phase 1
Overall status
Active, not recruiting
Start date
November 14, 2016
Completion date
December 31, 2026
Enrollment
100 (estimated)
Sites
24

Conditions

As the registry lists them; a condition with its own page is linked.

breast cancer, non small cell lung cancer